Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Next Previous
Trial Profile

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izalontamab brengitecan (Primary) ; Programmed cell death 1 receptor modulators (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Sichuan Baili Pharmaceutical

Most Recent Events

  • 23 Jul 2026 Planned End Date changed from 1 May 2026 to 1 Jun 2028.
  • 23 Jul 2026 Planned primary completion date changed from 1 May 2026 to 1 Dec 2026.
  • 09 Jul 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top